Hot Investor Mandate 4: Venture Fund Focuses on Therapeutics with a Precision Medicine Approach

21 Sep

A Boston-based venture capital firm that raised a fund in 2017 makes early stage equity investments of about $10-15 million, and can either lead investments or co-invest. The firm will consider investment opportunities worldwide.

The firm invests primarily in therapeutic opportunities. The firm is open to investing in any indication area; areas of high interest include precision medicine approaches, autoimmune diseases, oncology, neurology (particularly diseases with genetically defined populations), dermatology and ophthalmology. Generally, the firm is less interested in broad patient populations such as diabetes, Alzheimer’s disease, or cardiovascular disease. The firm generally invests from late preclinical (1-2 years pre-IND) through to Phase II, and prefers to invest in assets with good animal model and/or genetic evidence to support efficacy a3

nd target validation.

The firm only invests in privately held companies. The firm prefers to work with management teams that have had prior startup successes. The firm is an active investor and the partners have deep experience in company building, and is therefore interested in providing support on strategy, BD, recruiting and other areas of active management in addition to providing capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: